{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T15:32:34Z","timestamp":1792164754177,"version":"4.4.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,8]],"date-time":"2021-12-08T00:00:00Z","timestamp":1638921600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007208","name":"Vanderbilt-Ingram Cancer Center","doi-asserted-by":"publisher","award":["P30 CA68485"],"award-info":[{"award-number":["P30 CA68485"]}],"id":[{"id":"10.13039\/100007208","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["2P30 CA068485-14"],"award-info":[{"award-number":["2P30 CA068485-14"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["5UL1 RR024975-03"],"award-info":[{"award-number":["5UL1 RR024975-03"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01"],"award-info":[{"award-number":["R01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA214043"],"award-info":[{"award-number":["R01CA214043"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA243511"],"award-info":[{"award-number":["R01CA243511"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R21CA210210"],"award-info":[{"award-number":["R21CA210210"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000097","name":"National Center for Research Resources","doi-asserted-by":"publisher","award":["G20 RR030956"],"award-info":[{"award-number":["G20 RR030956"]}],"id":[{"id":"10.13039\/100000097","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neoplasia"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.neo.2021.12.002","type":"journal-article","created":{"date-parts":[[2021,12,19]],"date-time":"2021-12-19T23:21:55Z","timestamp":1639956115000},"page":"63-75","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Panobinostat enhances olaparib efficacy by modifying expression of homologous recombination repair and immune transcripts in ovarian cancer"],"prefix":"10.1016","volume":"24","author":[{"given":"Andrew J.","family":"Wilson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8915-3393","authenticated-orcid":false,"given":"Vijayalaxmi G","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1636-7942","authenticated-orcid":false,"given":"Fiona","family":"Yull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta A.","family":"Crispens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dineo","family":"Khabele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.neo.2021.12.002_bib0001","first-page":"7","article-title":"Cancer Statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"10106","key":"10.1016\/j.neo.2021.12.002_bib0002","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","article-title":"Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Coleman","year":"2017","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.neo.2021.12.002_bib0003","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ygyno.2015.12.020","article-title":"Efficacy and safety of olaparib monotherapy in germline BRCA1\/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy","volume":"140","author":"Domchek","year":"2016","journal-title":"Gynecol Oncol"},{"issue":"15","key":"10.1016\/j.neo.2021.12.002_bib0004","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa1105535","article-title":"Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer","volume":"366","author":"Ledermann","year":"2012","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.neo.2021.12.002_bib0005","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S1470-2045(14)70228-1","article-title":"Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial","volume":"15","author":"Ledermann","year":"2014","journal-title":"Lancet Oncol"},{"issue":"22","key":"10.1016\/j.neo.2021.12.002_bib0006","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.neo.2021.12.002_bib0007","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"18","author":"Pujade-Lauraine","year":"2017","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.neo.2021.12.002_bib0008","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1470-2045(16)30559-9","article-title":"Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial","volume":"18","author":"Swisher","year":"2017","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.neo.2021.12.002_bib0009","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S1470-2045(21)00073-5","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"22","author":"Poveda","year":"2021","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.neo.2021.12.002_bib0010","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.ygyno.2020.01.038","article-title":"CCNE1 and BRD4 co-amplification in high-grade serous ovarian cancer is associated with poor clinical outcomes","volume":"157","author":"Petersen","year":"2020","journal-title":"Gynecol Oncol"},{"issue":"7353","key":"10.1016\/j.neo.2021.12.002_bib0011","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","year":"2011","journal-title":"Nature"},{"issue":"48","key":"10.1016\/j.neo.2021.12.002_bib0012","doi-asserted-by":"crossref","first-page":"19489","DOI":"10.1073\/pnas.1314302110","article-title":"Synthetic lethality between CCNE1 amplification and loss of BRCA1","volume":"110","author":"Etemadmoghadam","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"10.1016\/j.neo.2021.12.002_bib0013","doi-asserted-by":"crossref","first-page":"795","DOI":"10.4161\/cbt.6.5.4007","article-title":"Drug-induced inactivation or gene silencing of class I histone deacetylases suppresses ovarian cancer cell growth: implications for therapy","volume":"6","author":"Khabele","year":"2007","journal-title":"Cancer Biol Ther"},{"issue":"11","key":"10.1016\/j.neo.2021.12.002_bib0014","doi-asserted-by":"crossref","first-page":"928","DOI":"10.4161\/cbt.9.11.11873","article-title":"The effects of the histone deacetylase inhibitor romidepsin (FK228) are enhanced by aspirin (ASA) in COX-1 positive ovarian cancer cells through augmentation of p21","volume":"9","author":"Son","year":"2010","journal-title":"Cancer Biol Ther"},{"issue":"6","key":"10.1016\/j.neo.2021.12.002_bib0015","doi-asserted-by":"crossref","first-page":"484","DOI":"10.4161\/cbt.12.6.15956","article-title":"The DNA damage mark pH2AX differentiates the cytotoxic effects of small molecule HDAC inhibitors in ovarian cancer cells","volume":"12","author":"Wilson","year":"2011","journal-title":"Cancer Biol Ther"},{"issue":"3","key":"10.1016\/j.neo.2021.12.002_bib0016","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.ygyno.2012.09.016","article-title":"Romidepsin (FK228) combined with cisplatin stimulates DNA damage-induced cell death in ovarian cancer","volume":"127","author":"Wilson","year":"2012","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.neo.2021.12.002_bib0017","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1757-2215-5-12","article-title":"Thailandepsins are new small molecule class I HDAC inhibitors with potent cytotoxic activity in ovarian cancer cells: a preclinical study of epigenetic ovarian cancer therapy","volume":"5","author":"Wilson","year":"2012","journal-title":"J Ovar Res"},{"issue":"3","key":"10.1016\/j.neo.2021.12.002_bib0018","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.ygyno.2014.03.007","article-title":"Suberoylanilide hydroxamic acid (SAHA) enhances olaparib activity by targeting homologous recombination DNA repair in ovarian cancer","volume":"133","author":"Konstantinopoulos","year":"2014","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.neo.2021.12.002_bib0019","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ygyno.2016.07.088","article-title":"Panobinostat sensitizes cyclin E high, homologous recombination-proficient ovarian cancer to olaparib","volume":"143","author":"Wilson","year":"2016","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.neo.2021.12.002_bib0020","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ygyno.2021.04.015","article-title":"Entinostat, a selective HDAC1\/2 inhibitor, potentiates the effects of olaparib in homologous recombination proficient ovarian cancer","volume":"162","author":"Gupta","year":"2021","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.neo.2021.12.002_bib0021","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1186\/s12943-015-0463-5","article-title":"Microenvironmental effects limit efficacy of thymoquinone treatment in a mouse model of ovarian cancer","volume":"14","author":"Wilson","year":"2015","journal-title":"Mol Cancer"},{"issue":"10","key":"10.1016\/j.neo.2021.12.002_bib0022","doi-asserted-by":"crossref","DOI":"10.3390\/cancers10100366","article-title":"Bipolar tumor-associated macrophages in ovarian cancer as targets for therapy","volume":"10","author":"Gupta","year":"2018","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.neo.2021.12.002_bib0023","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1186\/s12885-020-07450-8","article-title":"Increased canonical NF-kappaB signaling specifically in macrophages is sufficient to limit tumor progression in syngeneic murine models of ovarian cancer","volume":"20","author":"Hoover","year":"2020","journal-title":"BMC Cancer"},{"issue":"6","key":"10.1016\/j.neo.2021.12.002_bib0024","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1084\/jem.20080108","article-title":"Re-educating\" tumor-associated macrophages by targeting NF-kappaB","volume":"205","author":"Hagemann","year":"2008","journal-title":"J Exp Med"},{"issue":"1","key":"10.1016\/j.neo.2021.12.002_bib0025","doi-asserted-by":"crossref","first-page":"e30815","DOI":"10.1371\/journal.pone.0030815","article-title":"Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models","volume":"7","author":"Shen","year":"2012","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.neo.2021.12.002_bib0026","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1002\/cam4.3337","article-title":"Class I histone deacetylase inhibition promotes CD8 T cell activation in ovarian cancer","volume":"10","author":"McCaw","year":"2021","journal-title":"Cancer Med"},{"issue":"3","key":"10.1016\/j.neo.2021.12.002_bib0027","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s00262-017-2091-y","article-title":"The class I\/IV HDAC inhibitor mocetinostat increases tumor antigen presentation, decreases immune suppressive cell types and augments checkpoint inhibitor therapy","volume":"67","author":"Briere","year":"2018","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"10.1016\/j.neo.2021.12.002_bib0028","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ymthe.2020.09.034","article-title":"Olaparib suppresses MDSC recruitment via SDF1alpha\/CXCR4 axis to improve the anti-tumor efficacy of CAR-T cells on breast cancer in mice","volume":"29","author":"Sun","year":"2021","journal-title":"Mol Ther"},{"issue":"11","key":"10.1016\/j.neo.2021.12.002_bib0029","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.1016\/j.celrep.2018.11.054","article-title":"PARP inhibition elicits STING-dependent antitumor immunity in brca1-deficient ovarian cancer","volume":"25","author":"Ding","year":"2018","journal-title":"Cell Rep"},{"issue":"14","key":"10.1016\/j.neo.2021.12.002_bib0030","doi-asserted-by":"crossref","first-page":"3711","DOI":"10.1158\/1078-0432.CCR-16-3215","article-title":"PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression","volume":"23","author":"Jiao","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.neo.2021.12.002_bib0031","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1093\/carcin\/21.4.585","article-title":"Development of a syngeneic mouse model for events related to ovarian cancer","volume":"21","author":"Roby","year":"2000","journal-title":"Carcinogenesis"},{"issue":"4","key":"10.1016\/j.neo.2021.12.002_bib0032","doi-asserted-by":"crossref","first-page":"R36","DOI":"10.1186\/gb-2013-14-4-r36","article-title":"TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions","volume":"14","author":"Kim","year":"2013","journal-title":"Genome Biol"},{"issue":"12","key":"10.1016\/j.neo.2021.12.002_bib0033","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol"},{"key":"10.1016\/j.neo.2021.12.002_bib0034","doi-asserted-by":"crossref","first-page":"W77","DOI":"10.1093\/nar\/gkt439","article-title":"WEB-based GEne SeT AnaLysis Toolkit (WebGestalt): update 2013","volume":"41","author":"Wang","year":"2013","journal-title":"Nucleic Acids Res"},{"issue":"25","key":"10.1016\/j.neo.2021.12.002_bib0035","doi-asserted-by":"crossref","first-page":"21353","DOI":"10.18632\/oncotarget.3860","article-title":"Aberrant over-expression of COX-1 intersects multiple pro-tumorigenic pathways in high-grade serous ovarian cancer","volume":"6","author":"Wilson","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.neo.2021.12.002_bib0036","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","article-title":"Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors","volume":"22","author":"Chou","year":"1984","journal-title":"Adv Enzym Regul"},{"issue":"20","key":"10.1016\/j.neo.2021.12.002_bib0037","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1101\/gad.13.20.2633","article-title":"XRCC3 promotes homology-directed repair of DNA damage in mammalian cells","volume":"13","author":"Pierce","year":"1999","journal-title":"Genes Dev"},{"issue":"24","key":"10.1016\/j.neo.2021.12.002_bib0038","doi-asserted-by":"crossref","first-page":"3831","DOI":"10.1101\/gad.12.24.3831","article-title":"Double-strand break repair by interchromosomal recombination: suppression of chromosomal translocations","volume":"12","author":"Richardson","year":"1998","journal-title":"Genes Dev"},{"issue":"3","key":"10.1016\/j.neo.2021.12.002_bib0039","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.ygyno.2018.03.049","article-title":"The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer","volume":"149","author":"Wilson","year":"2018","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.neo.2021.12.002_bib0040","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/1757-2215-6-63","article-title":"Tracking NF-kappaB activity in tumor cells during ovarian cancer progression in a syngeneic mouse model","volume":"6","author":"Wilson","year":"2013","journal-title":"J Ovar Res"},{"key":"10.1016\/j.neo.2021.12.002_bib0041","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3389\/fonc.2017.00024","article-title":"The unique molecular and cellular microenvironment of ovarian cancer","volume":"7","author":"Worzfeld","year":"2017","journal-title":"Front Oncol"},{"key":"10.1016\/j.neo.2021.12.002_bib0042","doi-asserted-by":"crossref","first-page":"8687","DOI":"10.2147\/OTT.S216355","article-title":"Tumor-associated macrophages (TAMs): a critical activator in ovarian cancer metastasis","volume":"12","author":"Yin","year":"2019","journal-title":"OncoTargets Ther"},{"issue":"6","key":"10.1016\/j.neo.2021.12.002_bib0043","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.ccell.2019.05.004","article-title":"Cooperation between constitutive and inducible chemokines enables T cell engraftment and immune attack in solid tumors","volume":"35","author":"Dangaj","year":"2019","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.neo.2021.12.002_bib0044","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ygyno.2012.05.002","article-title":"VEGF induces ascites in ovarian cancer patients via increasing peritoneal permeability by downregulation of Claudin 5","volume":"127","author":"Herr","year":"2012","journal-title":"Gynecol Oncol"},{"issue":"6","key":"10.1016\/j.neo.2021.12.002_bib0045","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.prp.2008.01.011","article-title":"Maspin overexpression correlates with increased expression of vascular endothelial growth factors A, C, and D in human ovarian carcinoma","volume":"204","author":"Bolat","year":"2008","journal-title":"Pathol Res Pract"},{"key":"10.1016\/j.neo.2021.12.002_bib0046","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s13048-015-0177-8","article-title":"Thymoquinone enhances cisplatin-response through direct tumor effects in a syngeneic mouse model of ovarian cancer","volume":"8","author":"Wilson","year":"2015","journal-title":"J Ovar Res"},{"issue":"5","key":"10.1016\/j.neo.2021.12.002_bib0047","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1424672","article-title":"Prognosis of ovarian cancer is associated with effector memory CD8(+) T cell accumulation in ascites, CXCL9 levels and activation-triggered signal transduction in T cells","volume":"7","author":"Lieber","year":"2018","journal-title":"Oncoimmunology"},{"issue":"1","key":"10.1016\/j.neo.2021.12.002_bib0048","doi-asserted-by":"crossref","first-page":"3974","DOI":"10.1038\/s41467-019-11911-5","article-title":"Genetic programming of macrophages to perform anti-tumor functions using targeted mRNA nanocarriers","volume":"10","author":"Zhang","year":"2019","journal-title":"Nat Commun"}],"container-title":["Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476558621001068?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476558621001068?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T13:09:29Z","timestamp":1761484169000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1476558621001068"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":48,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S1476558621001068"],"URL":"https:\/\/doi.org\/10.1016\/j.neo.2021.12.002","relation":{},"ISSN":["1476-5586"],"issn-type":[{"value":"1476-5586","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Panobinostat enhances olaparib efficacy by modifying expression of homologous recombination repair and immune transcripts in ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neo.2021.12.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}